Redx Pharma PLC (AIM:REDX) said it is sellling its KRAS inhibitor programme to Nasdaq-listed Jazz Pharma Inc in a deal with a headline value of US$880 million. Under the terms of the transaction, Redx will receive an upfront US$10 million followed by US$870 million in development, regulatory, and sales milestone payments. It will also get royalties on any future sales. Its KRAS inhibitor programme targets one of the most challenging areas in cancer research. Mutations in the KRAS gene are prevalent across v ...

Redx to receive $10 million upfront; potential for up to $870 million in development, regulatory and sales milestone payments in addition to royalties on future net salesPreclinical program expands Jazz's pipeline of targeted oncology therapiesDUBLIN and ALDERLEY PARK, United Kingdom, Feb. 7, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and Redx Pharma plc (AIM: REDX) today announced that the companies have signed a definitive agreement under which Jazz will acquire Redx's KRAS (Kirsten rat ...

Ackun/iStock via Getty Images Shares of Jazz Pharmaceuticals (NASDAQ:JAZZ) have traded flat to somewhat lower since my November 2022 article and this was largely in line with what the average biotech stock was doing until early November of last year, the time when biotech stocks began to recover and Jazz's share price made no progress. YCharts My view at the time was that the stock was worth approximately $190 per share and more if the company could execute well against its 2025 and long-term goals of reach ...

About this content About Angela Harmantas Angela Harmantas is an Editor at Proactive. She has over 15 years of experience covering the equity markets in North America, with a particular focus on junior resource stocks. Angela has reported from numerous countries around the world, including Canada, the US, Australia, Brazil, Ghana, and South Africa for leading trade publications. Previously, she worked in investor relations and led the foreign direct investment program in Canada for the Swedish government ...

DUBLIN, Dec. 21, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced top-line results from the Phase 2 trial (NCT05178316) evaluating JZP150, an investigational small molecule selective fatty acid amide hydrolase (FAAH) inhibitor, on efficacy and safety in adults with post-traumatic stress disorder (PTSD). The trial did not meet the primary endpoint. There was not a statistically significant decrease in total PTSD symptom severity as measured by the Clinician Administered PTSD Scale ...

BRAF Mutant Mutant RAS or RTK CLASS 1 CLASS 2 CLASS 3 Driven B-RAF B-RAF Mutated B-RAF Mutated mEGFR / mRTK V600E Driven Dimer Driven RAS Driven mRAS RAS RAS RAS B-RAF B-RAF C-RAF / WT C-RAF / B-RAF C-RAF / C-RAF V600E D594X B-RAF A-RAF A-RAF G469X A-RAF MEK MEK MEK MEK Growth Inhibition Growth Inhibition Growth Inhibition Cell Growth Growth Inhibition █ 1st Gen. B-RAF V600E Inhibitor ● Pan-RAF Inhibitor JZP815 Examine antitumor activities across patient mutation subsets | --- | --- | |--------------------- ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2023 or ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 001-33500 JAZZ PHARMACEUTICALS PUBLIC LIMITED COMPANY (Exact name of registrant as specified in its charter) (State or other ju ...

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Q2 2023 Results Conference Call August 9, 2023 4:30 PM ET Company Participants Andrea Flynn - VP & Head, IR Bruce Cozadd - Chairman and Chief Executive Officer Renee Gala - Executive Vice President and Chief Financial Officer Dan Swisher - President and Chief Operating Officer Rob Iannone - Executive Vice President, Global Head of R&D Kim Sablich - Executive Vice President and General Manager of United States Conference Call Participants Jason Gerberry - Bank of Americ ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2023 or ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 001-33500 JAZZ PHARMACEUTICALS PUBLIC LIMITED COMPANY (Exact name of registrant as specified in its charter) (State or other jurisdi ...

13 d | --- | --- | --- | --- | --- | --- | |---------------|-----------------------------------|----------------------------------------------------------------|-------------------------------------|---------|-----------------------------------------------------------| | | | | EMAS | | Phase 3 Initiated - Fourth target indication | | Epidiolex | | | Japan (LGS/TSC/DS) | | Phase 3 First Patient Enrolled | | JZP150 | PTSD | | | | Phase 2 Top-line Data Readout expected late 2023 | | Suvecaltamide | Phase 2b es ...